This document provides an overview of a discussion on whether risk management and innovation in the healthcare industry are compatible. It includes introductions of several speakers who will provide different perspectives on this topic, including from "Big Pharma", regulators, economists, and end-users. The document also previews some of the key points that will be addressed such as defining risk, the types of risks faced by the industry, approaches to risk management and communication, and strategies to balance risk management with innovation.
1 of 15
Download to read offline
More Related Content
INSEAD Risk Management Introduction
1. Risk Management and Innovation in the Health Care Industry:
Are they (in)compatible?
Introduction
Dr. David Cocker
The Big Pharma point of view
Dr. Gerd Johnscher
Senior Partner, MDCPartners
Senior Consultant, Pharmakon
Former Senior VP, Adviser to the CEO, UCB
The Regulators point of view
Prof. Bruno Flamion
FUNDP University of Namur and CHMP
The Economists and Innovator point of view
Prof. Koenraad Debackere
Managing Director of K. U. Leuven R&D
Chairman of Gemma Frisius-Fonds
The End-users point of view
Mr. Jo De Cock
General Manager, RIZIV/INAMI
2. Risk Management and Innovation in the
healthcare industry
are they (in)compatible ?
Good evening,
my name is David Cocker and I am in the chair tonight.
3. Talking about risk is of course one of
the riskiest things one can do.
There are so many experts about !
( J.D.Remington, HSE, UK )
4. Whats risk ?
its very simple
The risk the first speaker will look up
wikipedia.org/historical_background/ the definition of risk.
5. Once risks was in the
hands of
others
Thx Peter Bernstein & Rembrandt
6. Most of us view risk as either acceptable
..or unacceptable
Thats if we have a choice ..
7. Reputational
People
Share price
Environmental
Ecotox
Compliance
Risk
Financial
Investments
Liabilities
Human Health
Efficacy
Safety
9. Study suggests heart attack risk
persisted for one year after
patients stopped taking Vioxx.
Oct. 14 issue of The Lancet. The study "also
appears to show the higher risk started soon
after patients began taking Vioxx, though" the
analysis "notes a small sample size precludes
a definitive finding on this issue."
13. time
RISK MANAGEMENT
RISK ASSESSMENT
Hazard identification
Dose (conc)-response (effect)
Exposure assessment
RISK CHARACTERIZATION
DECISIONS & ACTIONS
You need a plan
Management option:
Consequences of the options at
public health, economic, social &
political levels